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Edited by Lukas HuberAbstract This study investigated whether P-glycoprotein (Pgp)
and breast cancer resistance protein (BCRP) are linked in terms
of expression. RT-PCR and Western blot analyses showed that
the lung cancer cell line SK-MES-1/WT expressed BCRP. In
a drug-free state, BCRP expression was signiﬁcantly down-reg-
ulated in doxorubicin-resistant SK-MES-1/DX1000 cells over-
expressing Pgp. Pharmacological inhibitors (PSC833 or
verapamil) or siRNA for Pgp inhibited the down-regulation of
BCRP, which was conﬁrmed by confocal microscopy. PSC833
induced the phosphorylation of c-Jun NH2-terminal kinase
(JNK) and c-Jun, while the JNK inhibitor SP600125 inhibited
this eﬀect. Dominant negative c-Jun decreased the expression
of BCRP, but increased that of Pgp. These results indicate that
Pgp down-regulates BCRP expression in a drug-free state in
which JNK/c-Jun is involved.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The development of multidrug resistance (MDR) by tumor
cells is a major obstacle to successful cancer chemotherapy.
P-glycoprotein (Pgp), multidrug resistance-associated protein
1 (MRP1), and breast cancer resistance protein (BCRP) are
members of the ATP-binding cassette (ABC) superfamily of
membrane transporters [1–3]. These proteins are thought to
function as energy-dependent eﬄux pumps of a variety of
structurally diverse chemotherapeutic agents, thereby decreas-
ing intracellular drug accumulation. Although the physiologic
functions of ABC transporters are not well known, they are ex-
pressed constitutively in not only tumor cells, but also normal
cells [4].Abbreviations: MDR, multidrug resistance; Pgp, P-glycoprotein;
MRP1, multidrug resistance-associated protein 1; BCRP, breast cancer
resistance protein; ABC, ATP-binding cassette; JNK, c-Jun NH2-
terminal kinase; MAPK, mitogen-activated protein kinase; DN-c-Jun,
dominant negative form of c-Jun
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doi:10.1016/j.febslet.2008.06.036It has been proposed that an agent can suppress one or more
mechanisms of drug resistance while enhancing others, and
that one protein from one drug resistance gene can compensate
for the activity of the protein from another [5]. When it comes
to the relationships between the expressions of transporters,
there is so far no consensus. In this study, we focused on the
expression linkage between Pgp and BCRP with respect to
the involvement of c-Jun NH2-terminal kinase (JNK)/c-Jun
in the doxorubicin-resistant lung cancer cell subline SK-
MES-1/DX1000.2. Materials and methods
2.1. Cell culture
The SK-MES-1 cell line was obtained from the Cancer Research
Center in Seoul National University (South Korea) and cultured in
DMEM medium (GibcoBRL, Grand Island, NY, USA) with 10%
(v/v) heat-inactivated fetal bovine serum (Sigma, St. Louis, MO,
USA) at 37 C in a 5% (v/v) CO2 atmosphere. The doxorubicin-resis-
tant lung cancer cell subline SK-MES-1/DX1000 was selected from
the parental cell line SK-MES-1/WT after chronic exposure to doxoru-
bicin on an intermittent dosage schedule. Selection drugs were started
at 1 · IC50 and the concentration was increased at a rate of 50%, until
ﬁnally the cells were cultured in the presence of 1000 ng/ml doxorubi-
cin.
2.2. Cytotoxicity assay
The in vitro cytotoxicity of the drugs was determined using the MTT
assay [6].
2.3. Functional drug accumulation assay
The cells were washed twice with ice-cold PBS and then incubated in
5 lM daunorubicin (Sigma) with or without 10 lM PSC833 (Novartis
Pharmaceuticals, East Hanover, NJ, USA) in PBS for 1 h at 37 C.
The cells were subsequently analyzed for cellular drug ﬂuorescence
by ﬂow cytometry (FACSCalibur, Becton Dickinson, MA, USA), in
which a focused argon laser beam (480 nm) excited cells in a laminar
sheath ﬂow and their ﬂuorescence emissions (590 nm) were collected
to generate a histogram.
2.4. Western blot analysis
Western blotting was performed with slight modiﬁcation to the
method ﬁrst described by Towbin et al. [7]. Proteins were transferred
onto nitrocellulose membranes by electroblotting at 60 V overnight.
The membranes were incubated in 5% skim milk solution (5% bovine
serum albumin for mitogen-activated protein kinase (MAPKs)) in
TBST buﬀer for 1 h at room temperature (overnight at 4 C for MAP-
Ks), washed, and then incubated with primary antibodies (diluted
1:1000) for Pgp (C219, Signet Laboratories Inc., Dedham, MA,
USA), for BCRP (BXP-21, Kamiya Biomedical, Thousand Oaks,
CA, USA), for p-JNK and JNK (Cell Signaling Technologies, Beverly,
MA, USA) and for p-c-Jun and c-Jun (Santa Cruz Biotech, Santa
Cruz, CA, USA). The membranes were washed, and incubated withblished by Elsevier B.V. All rights reserved.
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1:2000, Sigma) and horseradish peroxidase-conjugated rabbit anti-
mouse IgG (diluted 1:2000, Cell Signaling Technologies) for 1 h. The
membranes were then stained using the detection reagent in the ECL
detection kit (Amersham, Piscataway, NJ, USA).2.5. RNA extraction and reverse transcription-polymerase chain reaction
(RT-PCR) assay
Total RNA was prepared from cells using the RNeasy midi kit (Qia-
gen, Hilden, Germany). MDR1, bcrp and b-actin mRNA transcripts
were detected using RT-PCR assays [8]. MDR1 expression was de-
tected with 3 0- and 5 0-primers (nucleotides 1179–1201 and 907–930,
respectively, of the cDNA sequence). BCRP expression was detected
with 3 0- and 5 0-primers (nucleotides 2136–2151 and 2590–2610, respec-
tively). As a control for RNA amounts, b-actin expression was de-
tected with 3 0- and 5 0-primers (nucleotides 2392–2412 and 1912–
1932, respectively). RNAs from each sample were reverse transcribed
using 200 units of Moloney murine leukemia virus reverse transcrip-
tase (Bethesda Research Laboratories, Gaithersburg, MD, USA) and
oligo-dT18 primer (Invitrogen, Carlsbad, CA, USA) for 1 h at 37 C.
The resulting cDNAs were sequentially ampliﬁed with 2.5 units of
Taq polymerase (Promega, Madison, WI, USA) and 10 pmol of each
primer in a GeneAmp PCR9600 (Perkin–Elmer–Cetus, Norwalk,
CT, USA) for 32 cycles (21 cycles for b-actin) of denaturation (95 C
for 30 s), annealing (53 C for 30 s; for MDR1, 65 C), and extension
(72 C for 30 s). After the last cycle, all PCR products were subjected
to a ﬁnal extension at 72 C for 5 min. The amount of each mRNA
transcript was normalized to that of b-actin.
2.6. Down-regulation of Pgp expression using siRNA
MDR1 siRNA (Santa Cruz) is a target-speciﬁc 20–25 nt siRNA. SK-
MES-1/DX1000 cells were washed three times with PBS and transfec-
ted with 10 lM siRNA (ﬁnal concentration) with Lipofectamine re-
agent (Invitrogen) according to the manufacturers protocol. After
30-h incubation, cells were rinsed with PBS and harvested for analysis
in the indicated time.
2.7. Double immunochemical staining
Cells were washed three times with PBS, ﬁxed and permeabilized in
cold methanol–acetone solution (1:1) for 30 min and washed at least
three times with PBS. The cells were incubated for 50 min with 1% nor-
mal goat serum in PBS and incubated at 37 C for 1 h with polyclonal
Pgp or BCRP antibodies (diluted 1:25; Santa Cruz) containing 0.1%
Triton X-100 in a humid chamber. After the cells were washed three
times with PBS, the cells were incubated with ﬂuorescence isothiocya-
nate (FITC)-conjugated goat anti-rabbit or Alexa Fluor 488-conju-
gated goat anti-mouse IgG at 37 C for 1 h, respectively. The cells
were washed twice with PBS, once with H2O and then observed on
an Olympus IX70 FV300 confocal microscope (Ina, Japan).
2.8. Construction of plasmids and transfection of dominant negative form
of c-Jun (DN-c-Jun)
Construction of a mammalian expression vector for the DN-c-Jun
was described previously [9]. Cells were transfected with the vector,
with or without insert, using Lipofectamine reagent (Invitrogen)
according to the manufacturers protocol. After 48-h incubation, cells
were rinsed with PBS, and protein was extracted.
2.9. Protein determination
Protein concentrations were determined by the Bradford method
[10].3. Results
3.1. Selection of doxorubicin-resistant SK-MES-1 subline SK-
MES-1/DX1000
We selected a doxorubicin-resistant lung cancer cell subline
SK-MES-1/DX1000 from the drug-sensitive parental cell SK-
MES-1/WT after chronic exposure to doxorubicin and were
ﬁnally cultured in the presence of 1000 ng/ml of doxorubicin.The SK-MES-1/DX1000 cells exhibited 67-fold resistance to
doxorubicin (Fig. 1A). In addition, the SK-MES-1/DX1000
cells displayed cross-resistance to paclitaxel (172-fold), vincris-
tine (20-fold) and mitoxantrone (7-fold).3.2. Expression and functional analysis of transporters in SK-
MES-1/DX1000 cells
Western blot analysis was carried out to conﬁrm which
MDR mechanism was involved in the SK-MES-1/DX1000
cells. RT-PCR and Western blot analyses showed that SK-
MES-1/WT cells expressed low levels of Pgp and high levels
of BCRP, whereas SK-MES-1/DX1000 cells overexpressed
Pgp and down-regulated expression of BCRP (Fig. 1 B). How-
ever, there was no diﬀerence in the level of MRP1 between the
cell lines (data not shown).
We observed a chemosensitizing eﬀect of PSC833 on the
growth of SK-MES-1/DX1000 cells in the presence of
1000 ng/ml doxorubicin. PSC833 reversed the resistance of
SK-MES-1/DX1000 cells to doxorubicin (Fig. 1C). In addi-
tion, ﬂow cytometry revealed that intracellular daunorubicin
concentration in SK-MES-1/DX1000 cells was less than that
in SK-MES-1/WT cells, and this concentration was increased
by 5 lM PSC833 (Fig. 1D).3.3. Eﬀects of Pgp inhibition on BCRP expression in SK-MES-
1/DX1000 cells
To determine whether Pgp was functionally involved in the
down-regulation of BCRP expression in SK-MES-1/DX1000
cells, the activity and expression of Pgp were inhibited by
Pgp inhibitors and MDR1 siRNA, respectively. PSC833 not
only decreased the level of MDR1 mRNA, but also simulta-
neously increased that of bcrp mRNA in SK-MES-1/DX1000
cells (Fig. 2).
The down-regulation of BCRP in SK-MES-1/DX1000 cells
was restored by treatment with PSC833 (Fig. 2). To investigate
if this eﬀect of PSC833 on the down-regulation of BCRP was
related to Pgp function, we used another Pgp inhibitor verap-
amil, which showed the same results as PSC833 with the excep-
tion of the eﬀects on mRNA expression of MDR1 (Fig. 2). To
knock-down MDR1 expression, MDR1 siRNA was transfec-
ted into SK-MES-1/DX1000 cells and then Pgp expression
was determined on days 1 and 3 using RT-PCR and Western
blot analyses, respectively. MDR1 siRNA decreased Pgp
mRNA and protein levels in SK-MES-1/DX1000 cells com-
pared to the expression levels in SK-MES-1/WT, but increased
those of BCRP on day 3 after transfection (Fig. 3A and B).
Double immunohistochemical staining revealed the same re-
sults as Western blot and RT-PCR analyses (Fig. 3C), i.e.,
BCRP expression is down-regulated with overexpression of
Pgp in the same cell.3.4. Involvement of c-Jun in PSC833-induced expression of
BCRP in SK-MES-1/DX1000 cells
Western blot analysis revealed that PSC833 induced not
only the phosphorylation of JNK but also expression and
phosphorylation of c-Jun in a time-dependent manner (Fig.
4A).
For inhibition studies, SK-MES-1/DX1000 cells were trea-
ted with 10 lM PSC833 for 3 days following pretreatment with
the p38 MAPK inhibitor SB203580, the extracellular signal-
regulated kinase inhibitor PD98059, the JNK inhibitor
Fig. 1. Characterization of SK-MES-1/WT and its doxorubicin-resistant subline SM-MES-1/DX1000. (A) Sensitivity to doxorubicin; (B) expression
proﬁles of Pgp and BCRP; (C) the chemosensitizing eﬀect of PSC833 in SK-MES-1/DX1000 cells; (D) the eﬀect of PSC833 on daunorubicin
accumulation in SK-MES-1/DX1000 cells. DX, doxorubicin; *, P < 0.05.
Fig. 2. The eﬀects of Pgp inhibitors on MDR1 and bcrp gene expression. RT-PCR and Western blot analyses were performed after treatment with
PSC833 or verapamil (each 10 lM) for 24 and 72 h, respectively, after each drug-free period. BCRP protein bands correspond to a tetramer.
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Fig. 3. The eﬀect of Pgp inhibition on BCRP expression in SK-MES-1/WT and DX1000 cells. RT-PCR assay (A) and Western blot analysis (B) were
performed in the indicated time after 30-h incubation with MDR1 siRNA. Double immunochemical staining (C) was carried out as described in
Section 2 after incubation with 10 lM PSC833 for 3 days.
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dithiocarbamate (PDTC). Of these inhibitors, only SP600125
inhibited the phosphorylation of c-Jun (Fig. 4B).
The transcription factor c-Jun plays a principal role in
down-regulation of MDR1 expression [11]. However, it is still
not known whether c-Jun is involved in BCRP expression. In
this study, we tested whether expression and activation of c-
Jun were involved in PSC833-induced up-regulation of BCRP
expression in SK-MES-1/DX1000 cells. Transient expression
of the DN-c-Jun decreased the expression of BCRP in SK-
MES-1/WT cells, but increased that of Pgp in SK-MES-1/
DX1000 cells (Fig. 4C).4. Discussion
We investigated how the expression levels of Pgp and BCRP
are linked in Pgp-overexpressing SK-MES-1/DX1000 cells.
The gene expression levels of three transporters in the lung
cancer cell line SK-MES-1/WT were BCRP > MRP1 > Pgp,
whereas those in its doxorubicin-resistant cell subline SK-
MES-1/DX1000 were Pgp > MRP1 > BCRP in a drug-free
state. Double immunohistochemical staining conﬁrmed thatthis ﬁnding was not due to contaminated clones. This inverse
relation between Pgp and BCRP expression is also supported
by a recent report that defective Pgp in mutant mdr1a(/)
mice was associated with increased bcrp mRNA at the mouse
blood–brain barrier [12]. There have been several reports of in-
verse relationships between MRP and Pgp [13–16]. In human
colon carcinoma cells, tumor necrosis factor-alpha inﬂuences
mrp and lrp gene expression in opposite ways [17], On the other
hand, positive correlations between bcrp and MDR1 expres-
sion have been reported [18,19]. Actually, inverse relations of
ABC transporters have not been a particular focus because
they are usually coexpressed, especially in the presence of anti-
cancer drugs. In this study, we also could not observe the
down-regulation of BCRP following overexpression of Pgp
in the presence of doxorubicin or within a short drug-free per-
iod of less than 7 days. It can be hypothesized that altered
expression of one ABC transporter can be compensated for
by other ABC transporters and that the expression of ABC
transporters in the presence of an anticancer drug would be
regulated in a supportive manner, but inversely regulated in
the absence of the anticancer drug.
The down-regulated expression of BCRP by overexpression
of Pgp in SK-MES-1/DX1000 cells was restored by treatment
Fig. 4. PSC833-induced activation of JNK/c-Jun (A and B) and the eﬀect of DN-c-Jun on Pgp and BCRP expression (C). DN-c-Jun, dominant
negative form of c-Jun.
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involvement of Pgp function rather than other eﬀects of the
drug itself. In addition, down-regulated expression of MDR1
after transfection of MDR1 siRNA showed the same results
as the inhibition of Pgp activity; these results indicate that
Pgp could play an important functional role in the down-reg-
ulation of BCRP. It can be hypothesized that Pgp might act as
an eﬄux pump of any BCRP inducer(s).The molecules that are
involved in BCRP expression in SK-MES-1/DX1000 cells re-
main to be determined.
Transcription factor c-Jun plays a principal role in down-
regulation of MDR1 expression [11]. However, it is still
not known whether c-Jun is involved in bcrp mRNA expres-
sion. We found that PSC833 induced phosphorylation of
JNK, and expression and phosphorylation of c-Jun in a
time-dependent manner. Among MAPK inhibitors, only
SP600125 inhibited PSC833-induced phosphorylation of
c-Jun. It has been shown that PSC833 promotes c-Jun phos-
phorylation via JNK, thereby resulting in the down-regula-
tion of Pgp and increased expression of BCRP, which was
conﬁrmed by transfection of the dominant negative form of
c-Jun.
Overall, these results indicate that Pgp can be co-ex-
pressed with BCRP in the presence of a drug, but function-
ally down-regulate BCRP expression in SK-MES-1/DX1000
cells in a drug-free state in which JNK/c-Jun pathway is in-
volved.Acknowledgements: This work was supported in part by Grants from
the Ministry of Science and Technology, Korea and the Korea Science
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